Onconetix, Inc. (ONCO): Nasdaq/NYSE listing notice — Onconetix faces Nasdaq delisting; stock at $0.10 or less for 10 days, hearing requested

Onconetix, Inc.

Nasdaq notified Onconetix on April 14, 2025, that its stock had closing bid of $0.10 or less for ten consecutive trading days.
Trading suspension scheduled for April 23, 2025, unless Nasdaq Hearings Panel grants a stay via requested hearing.
Company intends to request a hearing to stay suspension; no guarantee of continued listing.
Board postponed 2025 annual meeting from June 4, 2025; new date and record date to be announced later.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Onconetix, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(A)(iii)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(A)(iii)

Exact text from the filing

April 14, 2025, Nasdaq issued a further notice (the “Notice”) to the Company that it determined that the Company’s securities had a closing bid price of $0.10 or less for ten consecutive trading days. Accordingly, the Company is subject to the provisions under Nasdaq Listing Rule 5810(c)(3)(A)(iii). As a result, unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”), trading of the Common Stock will be suspended at the opening of business on April 23, 2025, and a Form 25-NSE will be filed with the Commission, which will remove the Company’s securities from

View on SEC.gov

93 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Onconetix, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-033295

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.